32 results on '"Comín-Colet J"'
Search Results
2. Recomendaciones para desarrollar Modelos Asistenciales de atención al paciente con Insuficiencia Cardiaca (Proyecto MAIC): Estudio Delphi
- Author
-
Comín-Colet, Josep, Alcober, Laia, Calero-Molina, Esther, Cobo, Marta, Corbella, Xavier, Cruzado, Concepción, Pinilla, José Manuel García, Gijón-Conde, Teresa, González-Franco, Álvaro, Llácer, Pau, Méndez-Bailón, Manuel, Muñiz, Javier, Núñez, Julio, Saturnino, Maria Teresa San, Muñoz, Cristina, Ibarrola, Cristina, Comin-Colet, J., Calero-Molina, E., Corbella, X., Muñiz, J., San Saturnino, M., and Ibarrola, C.
- Published
- 2022
- Full Text
- View/download PDF
3. Primera hospitalización por insuficiencia cardiaca: mortalidad hospitalaria y perfil del paciente
- Author
-
Masip, J., Formiga, F., Fernández-Castañer, M., Fernández, P., Comín-Colet, J., and Corbella, X.
- Published
- 2019
- Full Text
- View/download PDF
4. Documento de consenso de la Sociedad Española de Cardiología y la Sociedad Española de Medicina Interna sobre el diagnóstico y tratamiento del déficit de hierro en la insuficiencia cardíaca
- Author
-
Manito, N., Cerqueiro, J.M., Comín-Colet, J., García-Pinilla, J.M., González-Franco, A., Grau-Amorós, J., Peraira, J.R., and Manzano, L.
- Published
- 2017
- Full Text
- View/download PDF
5. Consenso para la mejora de la atención integral de los pacientes con insuficiencia cardíaca aguda: versión resumida
- Author
-
Manito Lorite, N., Manzano Espinosa, L., Llorens Soriano, P., Masip Utset, J., Comín Colet, J., Formiga Pérez, F., Herrero Puente, P., Delgado Jiménez, J., Montero-Pérez-Barquero, M., Jacob Rodríguez, J., López de Sá Areses, E., Pérez Calvo, J.I., Martín-Sánchez, F.J., and Miró Andreu, Ò.
- Published
- 2016
- Full Text
- View/download PDF
6. Hacia una atención integral y multidisciplinar en insuficiencia cardíaca
- Author
-
Méndez-Bailón, M. and Comín-Colet, J.
- Published
- 2022
- Full Text
- View/download PDF
7. Adjusted morbidity groups and geriatric assessment in older patients with acute coronary syndrome.
- Author
-
Ariza-Solé A, Formiga F, Monterde D, Vela E, Calvo E, and Comín-Colet J
- Subjects
- Humans, Aged, Female, Male, Aged, 80 and over, Morbidity trends, Spain epidemiology, Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome epidemiology, Acute Coronary Syndrome complications, Geriatric Assessment methods
- Published
- 2024
- Full Text
- View/download PDF
8. Population-based evaluation of the impact of socioeconomic status on clinical outcomes in patients with heart failure in integrated care settings.
- Author
-
Capdevila Aguilera C, Vela Vallespín E, Clèries Escayola M, Yun Viladomat S, Fernández Solana C, Alcober Morte L, Monterde Prat D, Hidalgo Quirós E, Calero Molina E, José Bazán N, Moliner Borja P, Piera Jiménez J, Ruiz Muñoz M, Corbella Virós X, Jiménez-Marrero S, Garay Melero A, Ramos Polo R, Alcoberro Torres L, Pons Riverola A, Enjuanes Grau C, and Comín-Colet J
- Subjects
- Humans, Hospitalization, Social Class, Retrospective Studies, Heart Failure epidemiology, Heart Failure therapy, Delivery of Health Care, Integrated
- Abstract
Introduction and Objectives: Low socioeconomic status (SES) is associated with poor outcomes in patients with heart failure (HF). We aimed to examine the influence of SES on health outcomes after a quality of care improvement intervention for the management of HF integrating hospital and primary care resources in a health care area of 209 255 inhabitants., Methods: We conducted a population-based pragmatic evaluation of the implementation of an integrated HF program by conducting a natural experiment using health care data. We included all individuals consecutively admitted to hospital with at least one ICD-9-CM code for HF as the primary diagnosis and discharged alive in Catalonia between January 1, 2015 and December 31, 2019. We compared outcomes between patients exposed to the new HF program and those in the remaining health care areas, globally and stratified by SES., Results: A total of 77 554 patients were included in the study. Death occurred in 37 469 (48.3%), clinically-related hospitalization in 41 709 (53.8%) and HF readmission in 29 755 (38.4%). On multivariate analysis, low or very low SES was associated with an increased risk of all-cause death and clinically-related hospitalization (all Ps <.05). The multivariate models showed a significant reduction in the risk of all-cause death (HR, 0.812; 95%CI, 0.723-0.912), clinically-related hospitalization (HR, 0.886; 95%CI, 0.805-0.976) and HF hospitalization (HR, 0.838; 95%CI, 0.745-0.944) in patients exposed to the new HF program compared with patients exposed to the remaining health care areas and this effect was independent of SES., Conclusions: An intensive transitional HF management program improved clinical outcomes, both overall and across SES strata., (Copyright © 2023 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
9. Chronotropic incompetence: rediscovering phenotypes in heart failure with preserved ejection fraction.
- Author
-
Jiménez-Marrero S, Ramos R, and Comín-Colet J
- Subjects
- Humans, Stroke Volume, Arrhythmias, Cardiac, Phenotype, Heart Rate, Exercise Test, Heart Failure diagnosis
- Published
- 2023
- Full Text
- View/download PDF
10. [Third-degree atrioventricular block associated with the SARS-CoV-2 mRNA vaccine].
- Author
-
Pons-Riverola A, Mañas P, Claver E, Meroño O, Comín-Colet J, and Anguera I
- Published
- 2023
- Full Text
- View/download PDF
11. [Components of geriatric assessment and therapeutic adherence in elderly patients with acute myocardial infarction].
- Author
-
Calvo E, Formiga F, Andreu-Periz L, Ariza-Solé A, Gómez-Hospital JA, and Comín-Colet J
- Subjects
- Aged, Aged, 80 and over, Female, Hospitalization, Humans, Male, Medication Adherence psychology, Treatment Adherence and Compliance, Geriatric Assessment, Myocardial Infarction drug therapy, Myocardial Infarction psychology
- Abstract
Background and Objective: Poor therapeutic adherence after acute myocardial infarction (AMI) can lead to early serious complications. Information on the impact of geriatric assessment on adherence is scarce. The objective of this study was to analyze, in older patients with AMI, the impact of geriatric assessment on therapeutic adherence 12 months after admission., Materials and Methods: A previous study randomized patients aged >75 years who had presented an AMI to a nursing health education program versus conventional management, evaluating the impact of this intervention on therapeutic adherence after 12 months. In-hospital geriatric assessment was performed. For this substudy, the adherence predictors were analyzed using binary logistic regression. Those patients who obtained adherence in the 4 tools were considered adherent: the Morisky-Green, Haynes-Sackett test, attendance at visits and correct withdrawal of drugs from the pharmacy., Results: A total of 119 patients with a mean age of 82.2 years were included. At one year, a total of 42 patients (35.3%) were adherent. The predictors of poor adherence in the final model were male sex, worse glomerular filtration rate, cognitive impairment, nutritional risk, not living alone and not belonging to the intervention group., Conclusions: The data of this series show a low therapeutic adherence in the elderly after an AMI. Cognitive impairment or nutritional risk was significantly associated with poorer adherence, contrary to a nursing intervention, which highlights the importance of health education and supervision in high-risk patients., (Copyright © 2021 SEGG. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
12. Coronary endothelial and microvascular function distal to polymer-free and endothelial cell-capturing drug-eluting stents. The randomized FUNCOMBO trial.
- Author
-
Gómez-Lara J, Oyarzabal L, Brugaletta S, Salvatella N, Romaguera R, Roura G, Fuentes L, Pérez Fuentes P, Ortega-Paz L, Ferreiro JL, Teruel L, Gracida M, Vaquerizo B, Sabaté M, Comín-Colet J, and Gómez-Hospital JA
- Subjects
- Coronary Angiography, Endothelial Cells, Humans, Microcirculation, Polymers, Prosthesis Design, Sirolimus pharmacology, Tomography, Optical Coherence, Treatment Outcome, Drug-Eluting Stents, Percutaneous Coronary Intervention
- Abstract
Introduction and Objectives: The vasomotor function of new-generation drug-eluting stents designed to enhance stent healing and reendothelialization is unknown. This study aimed to compare the endothelial function of the infarct-related artery (IRA) treated with bioactive circulating endothelial progenitor cell-capturing sirolimus-eluting stents (COMBO) vs polymer-free biolimus-eluting stents (BioFreedom) in ST-segment elevation myocardial infarction patients at 6 months. Secondary objectives were to compare the microcirculatory function of the IRA and stent healing at 6 months., Methods: Sixty patients were randomized to bioactive sirolimus-eluting stent vs polymer-free biolimus-eluting stents implantation. At 6 months, patients underwent coronary angiography with vasomotor, microcirculatory and optical coherence tomography examinations. Endothelial dysfunction of the distal coronary segment was defined as ≥ 4% vasoconstriction to intracoronary acetylcholine infusion., Results: Endothelial dysfunction was similarly observed between groups (64.0% vs 62.5%, respectively; P=.913). Mean lumen diameter decreased by 16.0 ±20.2% vs 16.1 ±21.6% during acetylcholine infusion (P=.983). Microcirculatory function was similar in the 2 groups: coronary flow reserve was 3.23 ±1.77 vs 3.23±1.62 (P=.992) and the index of microcirculatory resistance was 24.8±16.8 vs 21.3±12.0 (P=.440). Optical coherence tomography findings were similar: uncovered struts (2.3% vs 3.2%; P=.466), malapposed struts (0.1% vs 0.3%; P=.519) and major evaginations (7.1% vs 5.6%; P=.708) were observed in few cases., Conclusions: Endothelial dysfunction of the IRA was frequent and was similarly observed with new-generation drug-eluting stents designed to enhance stent reendothelialization at 6 months. Endothelial dysfunction was observed despite almost preserved microcirculatory function and complete stent coverage. Larger and clinically powered studies are needed to assess the role of residual endothelial dysfunction in ST-segment elevation myocardial infarction patients. Registered in ClinicalTrials.gov: NCT04202172., (Copyright © 2021 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
13. Noninferiority of heart failure nurse titration versus heart failure cardiologist titration. ETIFIC multicenter randomized trial.
- Author
-
Oyanguren J, Garcia-Garrido L, Nebot-Margalef M, Latorre-García P, Torcal-Laguna J, Comín-Colet J, Roure J, González-Costello J, Manito N, García-Pinilla JM, Sánchez-Paule Y, Varela-Román A, Moure M, Segovia-Cubero J, Soria T, Arana-Arri E, and Lekuona I
- Subjects
- Adrenergic beta-Antagonists, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Humans, Stroke Volume, Ventricular Function, Left, Cardiologists, Heart Failure drug therapy
- Abstract
Introduction and Objectives: Beta-blockers, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin-II-receptor-blockers (ARB), and mineralocorticoid-receptor antagonists decrease mortality and heart failure (HF) hospitalizations in HF patients with reduced left ventricular ejection fraction. The effect is dose-dependent. Careful titration is recommended. However, suboptimal doses are common in clinical practice. This study aimed to compare the safety and efficacy of dose titration of the aforementioned drugs by HF nurses vs HF cardiologists., Methods: ETIFIC was a multicenter (n=20) noninferiority randomized controlled open label trial. A total of 320 hospitalized patients with new-onset HF, reduced ejection fraction and New York Heart Association II-III, without beta-blocker contraindications were randomized 1:1 in blocks of 4 patients each stratified by hospital: 164 to HF nurse titration vs 156 to HF cardiologist titration (144 vs 145 analyzed). The primary endpoint was the beta-blocker mean relative dose (% of target dose) achieved at 4 months. Secondary endpoints included ACE inhibitors, ARB, and mineralocorticoid-receptor antagonists mean relative doses, associated variables, adverse events, and clinical outcomes at 6 months., Results: The mean±standard deviation relative doses achieved by HF nurses vs HF cardiologists were as follows: beta-blockers 71.09%±31.49% vs 56.29%±31.32%, with a difference of 14.8% (95%CI, 7.5-22.1), P <.001; ACE inhibitors 72.61%±29.80% vs 56.13%±30.37%, P <.001; ARB 44.48%±33.47% vs 43.51%±33.69%, P=.93; and mineralocorticoid-receptor antagonists 71%±32.12% vs 70.47%±29.78%, P=.86; mean±standard deviation visits were 6.41±2.82 vs 2.81±1.58, P <.001, while the number (%) of adverse events were 34 (23.6) vs 30 (20.7), P=.55; and at 6 months HF hospitalizations were 1 (0.69) vs 9 (5.51), P=.01., Conclusions: ETIFIC is the first multicenter randomized trial to demonstrate the noninferiority of HF specialist-nurse titration vs HF cardiologist titration. Moreover, HF nurses achieved higher beta-blocker/ACE inhibitors doses, with more outpatient visits and fewer HF hospitalizations. Trial registry number: NCT02546856., (Copyright © 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
14. Impact on clinical outcomes and health costs of deranged potassium levels in patients with chronic cardiovascular, metabolic, and renal conditions.
- Author
-
Jiménez-Marrero S, Cainzos-Achirica M, Monterde D, Vela E, Cleries M, García-Eroles L, Enjuanes C, Yun S, Garay A, Moliner P, Alcoberro L, Corbella X, and Comín-Colet J
- Subjects
- Aged, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Health Care Costs, Humans, Longitudinal Studies, Potassium, Heart Failure epidemiology, Hyperkalemia epidemiology, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic epidemiology
- Abstract
Introduction and Objectives: Potassium derangements are frequent among patients with chronic cardiovascular conditions. Studies on the associations between potassium derangements and clinical outcomes have yielded mixed findings, and the implications for health care expenditure are unknown. We assessed the population-based associations between hyperkalemia, hypokalemia and clinical outcomes and health care costs, in patients with chronic heart failure, chronic kidney disease, diabetes mellitus, hypertension, and ischemic heart disease., Methods: Population-based, longitudinal study including up to 36 269 patients from a health care area with at least one of the above-mentioned conditions. We used administrative, hospital and primary care databases. Participants were followed up between 2015 and 2017, were aged ≥ 55 years and had at least 1 potassium measurement. Four analytic designs were used to evaluate prevalent and incident cases and the use of renin-angiotensin-aldosterone system inhibitors., Results: Hyperkalemia was twice as frequent as hypokalemia. On multivariable-adjusted analyses, hyperkalemia was robustly and significantly associated with an increased risk of all-cause death (HR from Cox regression models ranging from 1.31-1.68) and with an increased odds of a yearly health care expenditure >85th percentile (OR, 1.21-1.29). Associations were even stronger in hypokalemic patients (HR for all-cause death, 1.92-2.60; OR for health care expenditure> percentile 85th, 1.81-1.85)., Conclusions: Experimental studies are needed to confirm whether the prevention of potassium derangements reduces mortality and health care expenditure in these chronic conditions. Until then, our findings provide observational evidence on the potential importance of maintaining normal potassium levels., (Copyright © 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
15. Neurohormonal treatment in tako-tsubo cardiomyopathy precipitated by COVID-19. Response.
- Author
-
Oyarzabal L, Gómez-Hospital JA, and Comín-Colet J
- Published
- 2021
- Full Text
- View/download PDF
16. Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain.
- Author
-
Manito Lorite N, Rubio-Rodríguez D, González Costello J, Díez López C, Enjuanes Grau C, Segovia-Cubero J, Delgado Jimenez JF, Campo Sien C, Rubio-Terrés C, and Comín-Colet J
- Subjects
- Administration, Intravenous, Aged, Aged, 80 and over, Costs and Cost Analysis, Female, Heart Failure economics, Humans, Male, Middle Aged, Outpatients, Risk Factors, Simendan economics, Spain epidemiology, Treatment Outcome, Ambulatory Care economics, Cardiotonic Agents economics, Cardiotonic Agents therapeutic use, Heart Failure drug therapy, Hydrazones economics, Hydrazones therapeutic use, Simendan therapeutic use
- Abstract
Introduction and Objectives: Advanced heart failure (HF) leads to high hospitalization and mortality rates. The LION-HEART study was a randomized, placebo-controlled clinical trial that evaluated the safety and efficacy of intravenous administration of intermittent doses of levosimendan in outpatients with advanced HF. The aim of the present study was to perform a cost analysis to determine whether the lower rate of hospitalizations for HF, observed in patients treated with levosimendan in the LION-HEART study, can generate savings for the Spanish national health system compared with the option of not treating patients with advanced HF., Methods: An economic model was used that included IC hospitalization rates from the LION-HEART study, the costs of hospitalization due to HF and those of the acquisition and intravenous administration of levosimendan. The time horizon of the analysis was 12 months. Two analyses were carried out, one deterministic and the other probabilistic (second-order Monte Carlo simulation)., Results: In the deterministic analysis, the total saving for each patient treated with levosimendan would amount to-€698.48. In the probabilistic analysis, the saving per patient treated with levosimendan would be-€849.94 (95%CI, €133.12 to-€2,255.31). The probability of savings with levosimendan compared with the no treatment option would be 94.8%., Conclusions: Intermittent ambulatory treatment with levosimendan can generate savings for the Spanish national health system compared with the option of not treating patients with advanced HF., (Copyright © 2019 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
17. Short term prognosis of heart failure after first hospital admission.
- Author
-
Masip J, Formiga F, Comín-Colet J, and Corbella X
- Subjects
- Aged, Emergency Service, Hospital statistics & numerical data, Female, Heart Failure complications, Heart Failure therapy, Hospitalization, Humans, Logistic Models, Long-Term Care, Male, Odds Ratio, Patient Transfer, Prognosis, Renal Insufficiency, Chronic epidemiology, Retrospective Studies, Spain epidemiology, Tertiary Care Centers, Time Factors, Heart Failure mortality, Patient Readmission statistics & numerical data
- Abstract
Background: Death and unexpected readmission are frequent among heart failure patients. We aimed to assess 30-day readmission and mortality rate as well as to identify predictive factors for patients discharged from a first HF related hospital admission., Methods and Results: Retrospective, single-center, cohort study, using administrative data from a tertiary care hospital in Barcelona, Spain. Patients discharged alive from a first HF related admission from 2010 to 2014 were assessed for 30-day death, readmission and adverse outcome rate. A Linear Logistic Regression Model was fitted for each outcome. The set accounted for 3642 patients; 50.1% female and 49.9% male. Mean age was 76 years (SD=12). 30-Days rates were 9.2% for readmission, 5.6% for death and 13.8% for adverse outcome. Admission to an ED within 30 days was strongly linked to readmission (OR=6.97), death (OR=2.31) and adverse outcome (OR=8.55), as well as chronic kidney disease (OR=1.44/1.61/2.86 respectively). Discharge to a Long Stay Care (LSC) facility was linked to lower readmission and adverse event rates (OR=.57 and OR=.15)., Conclusion: Pre and post-index discharge use of health care resources is related to adverse outcome rates. Our findings point out the potential benefit for a more tailored approach in the management of HF patients., (Copyright © 2019 Elsevier España, S.L.U. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
18. First hospital admission due to heart failure: In-hospital mortality and patient profile.
- Author
-
Masip J, Formiga F, Fernández-Castañer M, Fernández P, Comín-Colet J, and Corbella X
- Abstract
Objectives: We evaluated the patient profile and outcomes of first heart failure (HF) related hospital admission patients in the 2010-2014 period., Design: Retrospective, single-centre, cohort study., Setting: We used administrative data from a tertiary care hospital (Hospital Universitari de Bellvitge, Barcelona, Spain)., Participants: All patients with primary diagnosis of HF registered at the hospital discharge database from 2010 to 2014 were included, ruling out that HF was present 10 years prior to the current episode., Intervention: Primary care HF diagnosis status was assessed in order to distinguish new onset from no-new onset patients., Main Measures: Descriptive, bivariate and multivariate analysis were performed using age, previous primary care HF diagnosis and in-hospital death as grouping variables. Significant variables were fitted into a Linear logistic regression model for each outcome., Results: We selected 3,868 first HF-related admissions (56.8% of all HF episodes). In 1,220 patients (31.7%) HF was diagnosed by their primary care physician. Main pattern was a woman (OR=2.4), with higher prevalence of hypertension (OR=1.7), atrial fibrillation (OR=1.3), chronic kidney disease (OR=1.6) and mortality rate (9.8%). In-hospital death rate was 5.8%, age over 85 (OR=5.57), chronic kidney disease (OR=1.44) and length of stay over 7 days (OR=1.90) being the main contributors., Conclusions: First HF related admissions account for 56.7% of all HF episodes. Roughly one third of patients were already diagnosed by the time of their first hospital admission. Elderly women were the most frequent, but not the only, group of patients. Age, hospital stay and chronic kidney disease were the main contributors for in-hospital death., (Copyright © 2018 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
19. Planning to reduce 30-day adverse events after discharge of frail elderly patients with acute heart failure: design and rationale for the DEED FRAIL-AHF trial.
- Author
-
Martín-Sánchez FJ, Llopis García G, Llorens P, Jacob J, Herrero P, Gil V, Pastor AJ, López-Picado A, Fuentes Ferrer M, Rosselló X, Gil P, Díez Villanueva P, Calvo E, Méndez Bailón M, Cuesta-Triana F, González Armengol JJ, González Del Castillo J, Runtkle I, Vidán MT, Comín-Colet J, Cruz Jentoft A, Bueno H, Miró Ò, and Fernández Pérez C
- Subjects
- Acute Disease, Aged, Aged, 80 and over, Checklist, Clinical Protocols, Emergency Service, Hospital, Female, Follow-Up Studies, Heart Failure mortality, Hospitalization, Humans, Male, Matched-Pair Analysis, Prospective Studies, Research Design, Aftercare methods, Frail Elderly, Heart Failure therapy, Patient Care Planning, Patient Discharge, Patient Transfer
- Abstract
Objectives: To demonstrate the efficacy of a system for comprehensive care transfer (Multilevel Guided Discharge Plan [MGDP]) for frail older patients diagnosed with acute heart failure (AHF) and to validate the results of MGDP implementation under real clinical conditions. The MGDP seeks to reduce the number of adverse outcomes within 30 days of emergency department (ED) discharge., Material and Methods: We will enroll frail patients over the age of 70 years discharged home from the ED with a main diagnosis of AHF. The MGDP includes the following components: 1) a checklist of clinical recommendations and resource activations, 2) scheduling of an early follow-up visit, 3) transfer of information to the primary care doctor, and 4) written instructions for the patient. Phase 1 of the study will be a matched-pair cluster-randomized controlled trial. Ten EDs will be randomly assigned to the intervention group and 10 to the control group. Each group will enroll 480 patients, and the outcomes will be compared between groups. Phase 2 will be a quasi-experimental study of the intervention in 300 new patients enrolled by the same 20 EDs. The outcomes will be compared to those for each Phase-1 group. The main endpoint at 30 days will be a composite of 2 outcomes: revisits to an ED and/for hospitalization for AHF or cardiovascular death., Conclusion: The study will assess the efficacy and feasibility of comprehensive MGDP transfer of care for frail older AHF patients discharged home.
- Published
- 2019
20. Iron Deficiency Is a Determinant of Functional Capacity and Health-related Quality of Life 30 Days After an Acute Coronary Syndrome.
- Author
-
Meroño O, Cladellas M, Ribas-Barquet N, Poveda P, Recasens L, Bazán V, García-García C, Ivern C, Enjuanes C, Orient S, Vila J, and Comín-Colet J
- Subjects
- Acute Coronary Syndrome mortality, Aged, Aged, 80 and over, Exercise Tolerance, Female, Humans, Male, Middle Aged, Prospective Studies, Time Factors, Acute Coronary Syndrome complications, Acute Coronary Syndrome physiopathology, Iron Deficiencies, Quality of Life, Recovery of Function
- Abstract
Background and Objectives: Iron deficiency (ID) is a prevalent condition in patients with ischemic heart disease and heart failure. Little is known about the impact of ID on exercise capacity and quality of life (QoL) in the recovery phase after an acute coronary syndrome (ACS)., Methods: Iron status and its impact on exercise capacity and QoL were prospectively evaluated in 244 patients 30 days after the ACS. QoL was assessed by the standard EuroQoL-5 dimensions, EuroQoL visual analogue scale, and Heart-QoL questionnaires. Exercise capacity was analyzed by treadmill/6-minute walk tests. The effect of ID on cardiovascular mortality and readmission rate was also investigated., Results: A total of 46% of the patients had ID. These patients had lower exercise times (366±162 vs 462±155seconds; P<.001), metabolic consumption rates (7.9±2.9 vs 9.3±2.6 METS; P=.003), and EuroQoL-5 dimensions (0.76±0.25 vs 0.84±0.16), visual analogue scale (66±16 vs 72±17), and Heart-QoL (1.9±0.6 vs 2.2±0.6) scores (P<.05). ID independently predicted lower exercise times (OR, 2.9; 95%CI, 1.1-7.6; P=.023) and worse QoL (OR, 1.9; 95%CI, 1.1-3.3; P<.001) but had no effect on cardiovascular morbidity or mortality., Conclusions: ID, a prevalent condition in ACS patients, results in a poorer mid-term functional recovery, as measured by exercise capacity and QoL., (Copyright © 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
21. Consensus Document of the Spanish Society of Cardiology and the Spanish Society of Internal Medicine on the diagnosis and treatment of iron deficiency in heart failure.
- Author
-
Manito N, Cerqueiro JM, Comín-Colet J, García-Pinilla JM, González-Franco A, Grau-Amorós J, Peraira JR, and Manzano L
- Abstract
Iron deficiency in patients with heart failure is a medical problem of recent particular interest. This interest has resulted from the publication of several clinical trials that demonstrated that the administration of intravenous iron to such patients improved their functional capacity and even reduced the number of hospitalisations for heart failure decompensation. However, applying the evidence from these studies in clinical practice is still controversial, both in terms of the diagnostic criteria for iron deficiency (absolute and functional) and the optimal method for iron replenishment. This article is a consensus document that integrates the recommendations of the Spanish Society of Internal Medicine and the Spanish Society of Cardiology. The article reviews the scientific evidence and proposes a diagnostic and therapeutic performance protocol for iron deficiency in heart failure., (Copyright © 2016 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
22. Classification and Quality Standards of Heart Failure Units: Scientific Consensus of the Spanish Society of Cardiology.
- Author
-
Anguita Sánchez M, Lambert Rodríguez JL, Bover Freire R, Comín Colet J, Crespo Leiro MG, González Vílchez F, Manito Lorite N, Segovia Cubero J, Ruiz Mateas F, Elola Somoza FJ, and Íñiguez Romo A
- Subjects
- Adolescent, Adult, Aged, Consensus, Coronary Care Units classification, Critical Pathways standards, Equipment and Supplies, Hospital standards, Female, Health Information Systems standards, Health Personnel standards, Heart Failure diagnosis, Humans, Male, Middle Aged, Outcome Assessment, Health Care, Quality of Health Care standards, Spain, Terminology as Topic, Young Adult, Coronary Care Units standards, Heart Failure therapy
- Abstract
The prevalence of heart failure remains high and represents the highest disease burden in Spain. Heart failure units have been developed to systematize the diagnosis, treatment, and clinical follow-up of heart failure patients, provide a structure to coordinate the actions of various entities and personnel involved in patient care, and improve prognosis and quality of life. There is ample evidence on the benefits of heart failure units or programs, which have become widespread in Spain. One of the challenges to the analysis of heart failure units is standardization of their classification, by determining which "programs" can be identified as heart failure "units" and by characterizing their complexity level. The aim of this article was to present the standards developed by the Spanish Society of Cardiology to classify and establish the requirements for heart failure units within the SEC-Excellence project., (Copyright © 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
23. Transitions of Care Between Acute and Chronic Heart Failure: Critical Steps in the Design of a Multidisciplinary Care Model for the Prevention of Rehospitalization.
- Author
-
Comín-Colet J, Enjuanes C, Lupón J, Cainzos-Achirica M, Badosa N, and Verdú JM
- Subjects
- Acute Disease, Aftercare, Chronic Disease, Critical Pathways, Humans, Needs Assessment, Patient Care Planning, Patient Care Team, Social Support, Spain, Heart Failure therapy, Patient Readmission, Transitional Care organization & administration
- Abstract
Despite advances in the treatment of heart failure, mortality, the number of readmissions, and their associated health care costs are very high. Heart failure care models inspired by the chronic care model, also known as heart failure programs or heart failure units, have shown clinical benefits in high-risk patients. However, while traditional heart failure units have focused on patients detected in the outpatient phase, the increasing pressure from hospital admissions is shifting the focus of interest toward multidisciplinary programs that concentrate on transitions of care, particularly between the acute phase and the postdischarge phase. These new integrated care models for heart failure revolve around interventions at the time of transitions of care. They are multidisciplinary and patient-centered, designed to ensure continuity of care, and have been demonstrated to reduce potentially avoidable hospital admissions. Key components of these models are early intervention during the inpatient phase, discharge planning, early postdischarge review and structured follow-up, advanced transition planning, and the involvement of physicians and nurses specialized in heart failure. It is hoped that such models will be progressively implemented across the country., (Copyright © 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
24. The Limitations of the 6-Minute Walk Test as a Measurement Tool in Chronic Heart Failure Patients. Response.
- Author
-
Enjuanes C, Moliner-Borja P, Meroño O, and Comín-Colet J
- Subjects
- Chronic Disease, Exercise Test, Humans, Heart Failure, Walk Test
- Published
- 2016
- Full Text
- View/download PDF
25. Iron Deficiency in Patients With Acute Coronary Syndrome: Prevalence and Predisposing Factors.
- Author
-
Meroño O, Cladellas M, Ribas-Barquet N, Recasens L, Bazán V, and Comín-Colet J
- Subjects
- Aged, Aged, 80 and over, Anemia, Iron-Deficiency blood, Deficiency Diseases blood, Female, Ferritins blood, Humans, Male, Middle Aged, Prevalence, Risk Factors, Spain epidemiology, Transferrin metabolism, Acute Coronary Syndrome epidemiology, Anemia, Iron-Deficiency epidemiology, Deficiency Diseases epidemiology, Iron Deficiencies
- Published
- 2016
- Full Text
- View/download PDF
26. [Consensus on improving the care integrated of patients with acute heart failure].
- Author
-
Llorens P, Manito Lorite N, Manzano Espinosa L, Martín-Sánchez FJ, Comín Colet J, Formiga F, Jacob J, Delgado Jiménez J, Montero-Pérez-Barquero M, Herrero P, López de Sá Areses E, Pérez Calvo JI, Masip J, and Miró Ò
- Abstract
En: Acute heart failure (AHF) requires considerable use of resources, is an economic burden, and is associated with high complication and mortality rates in emergency departments, on hospital wards, or outpatient care settings. Diagnosis, treatment, and continuity of care are variable at present, leading 3 medical associations (for cardiology, internal medicine, and emergency medicine) to undertake discussions and arrive at a consensus on clinical practice guidelines to support those who manage AHF and encourage standardized decision making. These guidelines, based on a review of the literature and clinical experience with AHF, focus on critical points in the care pathway. Regarding emergency care, the expert participants considered the initial evaluation of patients with signs and symptoms that suggest AHF, the initial diagnosis, first decisions about therapy, monitoring, assessment of prognosis, and referral criteria. For care of the hospitalized patient, the group developed a protocol for essential treatment. Objectives for the management and treatment of AHF on discharge were also covered through the creation or improvement of multidisciplinary care systems to provide continuity of care.
- Published
- 2015
27. Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care.
- Author
-
Verdú JM, Comín-Colet J, Domingo M, Lupón J, Gómez M, Molina L, Casacuberta JM, Muñoz MA, Mena A, and Bruguera-Cortada J
- Subjects
- Aged, Aged, 80 and over, Area Under Curve, Comorbidity, Confidence Intervals, Cost-Benefit Analysis, Echocardiography, Doppler, Electrocardiography, Female, Heart Failure blood, Heart Failure drug therapy, Humans, Male, Point-of-Care Systems economics, Predictive Value of Tests, Primary Health Care, ROC Curve, Ventricular Dysfunction diagnosis, Heart Failure diagnosis, Natriuretic Peptide, Brain blood, Peptide Fragments blood
- Abstract
Introduction and Objectives: Measurement of natriuretic peptides may be recommended prior to echocardiography in patients with suspected heart failure. Cut-off point for heart failure diagnosis in primary care is not well established. We aimed to assess the optimal diagnostic cut-off value of N-terminal pro-B-type natriuretic peptide on a community population attended in primary care., Methods: Prospective diagnostic accuracy study of a rapid point-of-care N-terminal pro-B-type natriuretic peptide test in a primary healthcare centre. Consecutive patients referred by their general practitioners to echocardiography due to suspected heart failure were included. Clinical history and physical examination based on Framingham criteria, electrocardiogram, chest X-ray, N-terminal pro-B-type natriuretic peptide measurement and echocardiogram were performed. Heart failure diagnosis was made by a cardiologist blinded to N-terminal pro-B-type natriuretic peptide value, using the European Society of Cardiology diagnosis criteria (clinical and echocardiographic data)., Results: Of 220 patients evaluated (65.5% women; median 74 years [interquartile range 67-81]). Heart failure diagnosis was confirmed in 52 patients (23.6%), 16 (30.8%) with left ventricular ejection fraction <50% (39.6 [5.1]%). Median values of N-terminal pro-B-type natriuretic peptide were 715 pg/mL [interquartile range 510.5-1575] and 77.5 pg/mL [interquartile range 58-179.75] for patients with and without heart failure respectively. The best cut-off point was 280 pg/mL, with a receiver operating characteristic curve of 0.94 (95% confidence interval, 0.91-0.97). Six patients with heart failure diagnosis (11.5%) had N-terminal pro-B-type natriuretic peptide values <400 pg/mL. Measurement of natriuretic peptides would avoid 67% of requested echocardiograms., Conclusions: In a community population attended in primary care, the best cut-off point of N-terminal pro-B-type natriuretic peptide to rule out heart failure was 280 pg/mL. N-terminal pro-B-type natriuretic peptide measurement improve work-out diagnoses and could be cost-effectiveness., (Copyright © 2012 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
28. [Heart failure and heart transplant].
- Author
-
Almenar L, Díaz Molina B, Comín Colet J, and Pérez de la Sota E
- Subjects
- Acute Disease, Cardiac Surgical Procedures, Chronic Disease, Heart Transplantation statistics & numerical data, Humans, Hypertension, Pulmonary complications, Hypertension, Pulmonary therapy, Heart Failure surgery, Heart Failure therapy, Heart Transplantation trends
- Abstract
The mission of the Heart Failure and Transplantation Section of the Spanish Society of Cardiology is to study, to promote interest in, and to disseminate information about all aspects of myocardial dysfunction and heart transplantation. Heart failure is a highly prevalent condition that consumes a substantial proportion of healthcare resources. Consequently, there is considerable interest in the disorder. Numerous lines of clinical and preclinical research are actively being pursued and new ways of increasing knowledge about the disease are constantly being explored. The aim of this article was to describe the most recent developments concerning heart failure and its treatment. Firstly, the latest publications on chronic heart failure are analyzed. Then, there is a review of the most recent studies on resynchronization therapy and of clinical trials on acute heart failure. Thirdly, new developments in right heart dysfunction and pulmonary hypertension, and the findings of the Spanish Pulmonary Hypertension Registry are discussed. Finally, the latest information on ventricular assist devices and heart transplantation is presented. In addition, the most important data obtained from official transplantation registries (i.e. the Spanish Heart Transplantation Registry and the Spanish Post-Heart Transplantation Tumor Registry) are reviewed., (Copyright © 2011 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
29. Validation of the Spanish version of the Kansas city cardiomyopathy questionnaire.
- Author
-
Comín-Colet J, Garin O, Lupón J, Manito N, Crespo-Leiro MG, Gómez-Bueno M, Ferrer M, Artigas R, Zapata A, and Elosua R
- Subjects
- Chronic Disease, Female, Humans, Language, Male, Middle Aged, Prospective Studies, Spain, Heart Failure diagnosis, Quality of Life, Surveys and Questionnaires
- Abstract
Introduction and Objectives: The Kansas City Cardiomyopathy Questionnaire (KCCQ) is specifically designed to evaluate quality of life in patients with chronic heart failure (CHF). The purpose of this study was to assess the reliability, validity, and responsiveness to change of the Spanish version of the KCCQ., Methods: The multicenter study involved 315 patients with CHF. Patients were evaluated at baseline and at weeks 24 and 26. The KCCQ, the Minnesota Living with Heart Failure Questionnaire (MLHFQ), and the Short Form-36 (SF-36) were administered. Reliability was assessed in stable patients (n=163) by examining test-retest and internal consistency measures between weeks 24 and 26. Validity was evaluated at baseline (n=315) by determining how KCCQ scores varied with New York Heart Association functional class and by comparing scores with those on similar domains of the MLHFQ and SF-36. Responsiveness to change was assessed in patients who experienced significant clinical improvement between baseline and week 24 (n=31) by determining the effect size., Results: Reliability coefficients ranged between 0.70 and 0.96 for the different domains. Mean KCCQ scores varied significantly with New York Heart Association functional class (P<.001). Correlations with comparable domains on the other questionnaires were acceptable (e.g. for physical limitation, they were between 0.77 and 0.81). The changes observed at 24 weeks in the majority of KCCQ scores in the subsample that improved corresponded to a moderate effect size (i.e. 0.4-0.6)., Conclusions: The Spanish version of the KCCQ has good metric properties (i.e. validity, reliability and responsiveness), which make it suitable for use in evaluating quality of life in Spanish CHF patients., (Copyright © 2010 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
30. [Hyponatremia in heart failure: physiopathology and pharmacological approach].
- Author
-
Robledo GG, Cantillo DS, and Comín Colet J
- Subjects
- Antidiuretic Hormone Receptor Antagonists, Arginine Vasopressin physiology, Benzamides pharmacology, Benzamides therapeutic use, Benzazepines pharmacology, Benzazepines therapeutic use, Body Water metabolism, Brain Edema etiology, Brain Edema prevention & control, Demyelinating Diseases chemically induced, Demyelinating Diseases prevention & control, Diuresis, Diuretics therapeutic use, Double-Blind Method, Heart Failure metabolism, Heart Failure physiopathology, Humans, Hyponatremia drug therapy, Hyponatremia physiopathology, Kidney physiopathology, Multicenter Studies as Topic, Natriuresis, Pyrroles pharmacology, Pyrroles therapeutic use, Randomized Controlled Trials as Topic, Receptors, Vasopressin physiology, Renin-Angiotensin System physiology, Saline Solution, Hypertonic administration & dosage, Saline Solution, Hypertonic adverse effects, Saline Solution, Hypertonic therapeutic use, Sympathetic Nervous System physiopathology, Tolvaptan, Heart Failure complications, Hyponatremia etiology
- Abstract
Hyponatremia is a well-known adverse prognostic factor in patients with chronic heart failure. The mechanisms linking hyponatremia with poor outcomes in these patients are not well understood and may be related to the presence of the abnormal management of water and neurohormonal activation seen in patients with chronic heart failure, which in turn are associated with a worse prognosis. Possibly, free-water retention exceeds the degree of sodium retention in chronic heart failure, which could partially explain the hyponatremia found in these patients. There are several therapeutic strategies for the management of hyponatremia in patients with chronic heart failure, including fluid restriction, high-dose diuretic administration and infusion of hypertonic saline, but none has been proven to be very effective. Recently, vasopressin antagonism through vasopressin receptor antagonists has opened up a new way of treating hyponatremia in these patients by enhancing aquaresis. Several agents are available but their possible impact on morbidity and mortality in patients with hyponatremia and chronic heart failure requires elucidation., (Copyright © 2010 Sociedad Española de Endocrinología y Nutrición. Published by Elsevier Espana. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
31. [Advances in heart failure].
- Author
-
Comín Colet J, Muñoz Aguilera R, Cuenca Castillo JJ, and Delgado Jiménez JF
- Subjects
- Acute Disease, Assisted Circulation, Cardiac Surgical Procedures, Cardiovascular Agents therapeutic use, Chronic Disease, Heart Failure drug therapy, Heart Failure surgery, Humans, Heart Failure therapy
- Abstract
This article reports on the most significant developments in the field of heart failure in the past year. Principal innovations in the management of chronic heart failure are explained, including the most important features of new management models for patients with chronic heart failure and the main advances in drug therapy and in the use of and indications for cardiac devices in these patients. In addition, recent progress in the treatment of advanced heart failure, with particular emphasis on acute heart failure, is reviewed. Novel approaches to the surgical management of patients with heart failure, including new contributions in the field of the circulatory support, are also highlighted in this update.
- Published
- 2009
- Full Text
- View/download PDF
32. [Prevalence and clinical course of patients in Spain with acute myocardial infarction and severely depressed ejection fraction who meet the criteria for automatic defibrillator implantation].
- Author
-
Martí Almor J, Delclós Baulies M, Delclós Urgell J, Comín Colet J, Cladellas Capdevila M, and Bruguera Cortada J
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Myocardial Infarction epidemiology, Patient Selection, Retrospective Studies, Spain epidemiology, Defibrillators, Implantable statistics & numerical data, Myocardial Infarction physiopathology, Myocardial Infarction therapy
- Abstract
The Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II has broadened the indications for cardioverter defibrillator implantation. We present a retrospective study designed to estimate the number of patients in Spain eligible for an implantable defibrillator according to the MADIT-II criteria. From January 1999 to October 2002, 758 consecutive patients were admitted to our center with the diagnosis of acute myocardial infarction. Sixty-seven had a left ventricular ejection fraction < or = 30% (mean, 23[5]) and were not eligible for revascularization. Excluding patients older than 80 years and patients with marked co-morbidity, 47 patients met the MADIT-II criteria for an implantable defibrillator. After a mean follow-up of 18 months, there were 20 deaths, 6 of which were considered sudden. In conclusion, application of the MADIT-II criteria for defibrillator implantation may benefit 6% of the patients with myocardial infarction in Spain. This proportion translates as 4110 defibrillator implantations.
- Published
- 2004
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.